MedPath

Omega-3 Polyunsaturated Fatty Acids in Youth With ADHD

Not Applicable
Completed
Conditions
Attention Deficit Hyperactivity Disorder
ADHD
Interventions
Dietary Supplement: n-3 Polyunsaturated fatty acid
Dietary Supplement: Placebo
Registration Number
NCT03542643
Lead Sponsor
China Medical University Hospital
Brief Summary

N-3 polyunsaturated fatty acids(N-3 PUFAs) is important in balancing the immune function and crucial for the developing brain. Deficiency in n-3 PUFAs might be linked to the poor cognitive performances resulting in inattention and hyperactivity in youth with attention deficit hyperactivity disorder (ADHD). N-3 PUFAs appears to be a promising treatment that is safe, beneficial to youth with ADHD. In this proposal, investigators aim the test the hypothesis that n-3 polyunsaturated fatty acids will be more effective than placebo in improving cognitive function in youth with ADHD after 12 weeks of intervention.

Detailed Description

This is a 1-year study and a randomized, double-blind, and placebo controlled Clinical the study. investigators plan to enrol 100 subjects from Child and Adolescent Psychiatry Outpatient Clinic of China Medical University Hospital.Participants will be randomized into omega-3 polyunsaturated fatty acids or placebo group.The intervention period is 12 weeks. Evaluation of the cognitive function ( using Continuous Performance Test 3rd Edition ) of the subjects who are enrolled into the study will take place at baseline and after the 12th week. The symptom severity of ADHD will be measured with Swanson, Nolan, Pelham Questionnaire (SNAP-IV) at baseline, 2,4,8, and 12 weeks. The plasma level of n-3 polyunsaturated fatty acids, blood and salivary inflammatory markers will also be measured at the beginning and at the end of the study.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
105
Inclusion Criteria
  • DSM-5 diagnosed ADHD
  • Age 6-18 years old at time of enrolment
  • Conner's rating scares (CPRS) with scores >= 2 standard deviations
  • drug native or no medication use for past 6 months
  • Signed informed consent
Exclusion Criteria
  • Intelligence quotient <70
  • Comorbid other psychiatric disorders, such as autism spectrum disorders, anxiety disorders, conduct disorders, schizophrenia, major depressive disorders and bipolar spectrum disorders
  • Comorbid physical disorders, such as thyroid dysfunction, cerebral palsy
  • Current using omega-3 supplements
  • Allergy to omega-3

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
N-3 polyunsaturated fatty acidsn-3 Polyunsaturated fatty acidn-3 polyunsaturated fatty acids dosage of 1g of Eicosapentaenoic acid(EPA)
PlaceboPlaceboolive oil ethyl esters
Primary Outcome Measures
NameTimeMethod
Changes in Continuous Performance Test Raw Scores at 12 weeksWeek 0 and Week 12

Correct Detection: This indicates the number of times the client responded to the target stimulus. Higher rates of correct detections indicate better attentional capacity.

Reaction times: This measures the amount of time between the presentation of the stimulus and the client's response.

Omission errors: This indicates the number of times the target was presented, but the client did not respond/click the mouse. High omission rates indicate that the subject is either not paying attention (distractibility) to stimuli or has a sluggish response.

Commission errors: This score indicates the number of times the client responded but no target was presented. A fast reaction time and high commission error rate points to difficulties with impulsivity. A slow reaction time with high commission and omission errors, indicates inattention in general.

Secondary Outcome Measures
NameTimeMethod
Changes in SNAP-IV Scores for Inattention, Hyperactivity and Total ADHD Symptom SeverityWeek 0, 2,4,8,12

Inattention: items 1-9 Hyperactivity: items 10-18 Total ADHD: items 1-18 the greater the scores on SNAP-IV indicate the greater the severity of ADHD symptoms

Trial Locations

Locations (1)

China Medical University

🇨🇳

Taichung, Taiwan

© Copyright 2025. All Rights Reserved by MedPath